Osella M, Riba A, Testori A, et al. Interplay of microRNA and epigenetic regulation in the human regulatory network. Front Genet. 2014;5:345.
Zhao S, Wang Y, Liang Y, et al. MicroRNA-126 regulates DNA methylation in CD4+ T cells and contributes to systemic lupus erythematosus by targeting DNA methyltransferase 1. Arthritis Rheumatol. 2011;63:1376–86.
Moutinho C, Esteller M. MicroRNAs and epigenetics. Adv Cancer Res. 2017;135:189–220.
Oglesby IK, Bray IM, Chotirmall SH, et al. miR-126 is downregulated in cystic fibrosis airway epithelial cells and regulates TOM1 expression. J Immunol. 2010;184:1702–9.
Haider BA, Baras AS, McCall MN, et al. A critical evaluation of microRNA biomarkers in non-neoplastic disease. PLoS ONE. 2014;9:e89565.
Mukohyama J, Shimono Y, Minami H, et al. Roles of microRNAs and RNA-binding proteins in the regulation of colorectal cancer stem cells. Cancers. 2017;9(10):143.
Song Y, Yu X, Zang Z, et al. Circulating or tissue microRNAs and extracellular vesicles as potential lung cancer biomarkers: a systematic review. Int J Biol Markers. 2017;33(1):3–9.
An Q, Han C, Zhou Y, et al. Matrine induces cell cycle arrest and apoptosis with recovery of the expression of miR-126 in the A549 non-small cell lung cancer cell line. Mol Med Rep. 2016;14:4042–8.
Dong Y, Fu C, Guan H, et al. Prognostic significance of miR-126 in various cancers: a meta-analysis. OncoTargets Ther. 2016;9:2547–55.
Kong R, Ma Y, Feng J, et al. The crucial role of miR-126 on suppressing progression of esophageal cancer by targeting VEGF-A. Cell Mol Biol Lett. 2016;21:3.
Salajegheh A, Vosgha H, Rahman MA, et al. Interactive role of miR-126 on VEGF-A and progression of papillary and undifferentiated thyroid carcinoma. Hum Pathol. 2016;51:75–85.
Yan J, Dang Y, Liu S, et al. LncRNA HOTAIR promotes cisplatin resistance in gastric cancer by targeting miR-126 to activate the PI3K/AKT/MRP1 genes. Tumour Biol. 2016;37(12):16345–55.
Fiala O, Pitule P, Hosek P, et al. The association of miR-126-3p, miR-126-5p and miR-664-3p expression profiles with outcomes of patients with metastatic colorectal cancer treated with bevacizumab. Tumour Biol. 2017;39:1010428317709283.
Guinn D, Lehman A, Fabian C, et al. The regulation of tumor-suppressive microRNA, miR-126, in chronic lymphocytic leukemia. Cancer Med. 2017;6:778–87.
Bai Y, Lu W, Han N, et al. Functions of miR126 and innate immune response. Yi chuan= Hereditas. 2014;36:631–6.
Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68:1–26.
Chavez-Valencia RA, Chiaroni-Clarke RC, Martino DJ et al. The DNA methylation landscape of CD4+ T cells in oligoarticular juvenile idiopathic arthritis. J Autoimmun. 2018;86:29–38.
Coppede F. Epigenetics and autoimmune thyroid diseases. Front Endocrinol. 2017;8:149.
Jerram ST, Dang MN, Leslie RD. The role of epigenetics in type 1 diabetes. Curr Diab Rep. 2017;17:89.
Tavasolian F, Abdollahi E, Rezaei R et al. Altered expression of microRNAs in rheumatoid arthritis. J Cell Biochem 2018;119:478–87.
Wang Z, Chang C, Peng M, et al. Translating epigenetics into clinic: focus on lupus. Clin Epigenetics. 2017;9:78.
Pan W, Zhu S, Yuan M, et al. MicroRNA-21 and microRNA-148a contribute to DNA hypomethylation in lupus CD4+ T cells by directly and indirectly targeting DNA methyltransferase 1. J Immunol. 2010;184:6773–81.
Qin H, Zhu X, Liang J, et al. MicroRNA-29b contributes to DNA hypomethylation of CD4+ T cells in systemic lupus erythematosus by indirectly targeting DNA methyltransferase 1. J Dermatol Sci. 2013;69:61–7.
Kaplan MJ, Lu Q, Wu A, et al. Demethylation of promoter regulatory elements contributes to perforin overexpression in CD4+ lupus T cells. J Immunol. 2004;172:3652–61.
Oelke K, Lu Q, Richardson D, et al. Overexpression of CD70 and overstimulation of IgG synthesis by lupus T cells and T cells treated with DNA methylation inhibitors. Arthritis Rheumatol. 2004;50:1850–60.
Lu Q, Wu A, Richardson BC. Demethylation of the same promoter sequence increases CD70 expression in lupus T cells and T cells treated with lupus-inducing drugs. J Immunol. 2005;174:6212–9.
Zhao M, Wu X, Zhang Q, et al. RFX1 regulates CD70 and CD11a expression in lupus T cells by recruiting the histone methyltransferase SUV39H1. Arthritis Res Ther. 2010;12:R227.
Yang G, Wu D, Zeng G, et al. Correlation between miR-126 expression and DNA hypomethylation of CD4+ T cells in rheumatoid arthritis patients. Int J Clin Exp Pathol. 2015;8:8929–36.
Atzeni F, Sarzi-Puttini P. Anti-cytokine antibodies for rheumatic diseases. Curr Opin Investig Drugs. 2009;10:1204–11.
Castro-Villegas C, Perez-Sanchez C, Escudero A, et al. Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNFα. Arthritis Res Ther. 2015;17:49.
Karouzakis E, Gay RE, Gay S, et al. Epigenetic control in rheumatoid arthritis synovial fibroblasts. Nat Rev Rheumatol. 2009;5:266–72.
McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. New Engl J Med. 2011;365:2205–19.
Li H, Wan A. Apoptosis of rheumatoid arthritis fibroblast-like synoviocytes: possible roles of nitric oxide and the thioredoxin 1. Mediat Inflamm. 2013;2013:953462.
Hayer S, Pundt N, Peters MA, et al. PI3Kγ regulates cartilage damage in chronic inflammatory arthritis. FASEB J. 2009;23:4288–98.
Wang J, Zhang W, Zou H, et al. 10-Hydroxy-2-decenoic acid inhibiting the proliferation of fibroblast-like synoviocytes by PI3K-AKT pathway. Int Immunopharmacol. 2015;28:97–104.
Gao J, Zhou XL, Kong RN, et al. microRNA-126 targeting PIK3R2 promotes rheumatoid arthritis synovial fibro-blasts proliferation and resistance to apoptosis by regulating PI3K/AKT pathway. Exp Mol Pathol. 2016;100:192–8.
Jia S, Zhang S, Yuan H, et al. Lunasin inhibits cell proliferation via apoptosis and reduces the production of proinflammatory cytokines in cultured rheumatoid arthritis synovial fibroblasts. Biomed Res Int. 2015;2015:346839.
Qu Y, Wu J, Deng JX, et al. MicroRNA-126 affects rheumatoid arthritis synovial fibroblast proliferation and apoptosis by targeting PIK3R2 and regulating PI3K-AKT signal pathway. Oncotarget. 2016;7:74217–26.
Murata K, Furu M, Yoshitomi H, et al. Comprehensive microRNA analysis identifies miR-24 and miR-125a-5p as plasma biomarkers for rheumatoid arthritis. PLoS ONE. 2013;8:e69118.
Chen CY, Su CM, Hsu CJ, et al. CCN1 promotes VEGF production in osteoblasts and induces endothelial progenitor cell angiogenesis by inhibiting miR-126 expression in rheumatoid arthritis. J Bone Miner Res. 2017;32:34–45.
Golder V, Hoi A. Systemic lupus erythematosus: an update. Med J Aust. 2017;206:215–20.
Gordon C, Amissah-Arthur MB, Gayed M et al. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology. 2018;57(1):e1–e45.
Husakova M. MicroRNAs in the key events of systemic lupus erythematosus pathogenesis. Biomed Pap Med Fac Palacky Univ Olomouc. 2016;160:327–42.
Liu YJ, Fan WJ, Bai JZ. microRNA-126 expression and its mechanism of action in patients with systemic lupus erythematosus. Eur Rev Med Pharmacol Sci. 2015;19:3838–42.
Rieckmann P, Boyko A, Centonze D, et al. Future MS care: a consensus statement of the MS in the 21st Century Steering Group. J Neurol. 2013;260:462–9.
Zheleznyakova GY, Piket E, Marabita F, et al. Epigenetic research in multiple sclerosis: progress, challenges, and opportunities. Physiol Genom. 2017;49:447–61.
Chen J, Zhu J, Wang Z, et al. MicroRNAs correlate with multiple sclerosis and neuromyelitis optica spectrum disorder in a Chinese population. Med Sci Monit Int Med J Exp Clin Res. 2017;23:2565–83.
Cerutti C, Edwards LJ, de Vries HE, et al. miR-126 and miR-126* regulate shear-resistant firm leukocyte adhesion to human brain endothelium. Sci Rep. 2017;7:45284.
Garcia-Rodriguez S, Arias-Santiago S, Orgaz-Molina J, et al. Abnormal levels of expression of plasma microRNA-33 in patients with psoriasis. Actas Dermo-Sifiliograficas. 2014;105:497–503.
Eberle FC, Brück J, Holstein J et al. Recent advances in understanding psoriasis [version 1; referees: 2 approved]. F1000Research. 2016;5(F1000 Faculty Rev):770. https://doi.org/10.12688/f1000research.7927.1.
Schleicher SM. Psoriasis: pathogenesis, assessment, and therapeutic update. Clin Podiatr Med Surg. 2016;33:355–66.
Pivarcsi A, Meisgen F, Xu N, et al. Changes in the level of serum microRNAs in patients with psoriasis after antitumour necrosis factor-alpha therapy. Br J Dermatol. 2013;169:563–70.
Satoh M, Minami Y, Takahashi Y, et al. A cellular MicroRNA, let-7i, is a novel biomarker for clinical outcome in patients with dilated cardiomyopathy. J Cardiac Fail. 2011;17:923–9.
Krejci J, Mlejnek D, Sochorova D, et al. Inflammatory cardiomyopathy: a current view on the pathophysiology, diagnosis, and treatment. Biomed Res Int. 2016;2016:4087632.
Comarmond C, Cacoub P. Myocarditis in auto-immune or auto-inflammatory diseases. Autoimmun Rev. 2017;16:811–6.
Kim E, Cook-Mills J, Morgan G, et al. Increased expression of vascular cell adhesion molecule 1 in muscle biopsy samples from juvenile dermatomyositis patients with short duration of untreated disease is regulated by miR-126. Arthritis Rheumatol. 2012;64:3809–17.
Castro D, Moreira M, Gouveia AM, et al. MicroRNAs in lung cancer. Oncotarget. 2017;8:81679–85.
Idda ML, Munk R, Abdelmohsen K, et al. Noncoding RNAs in Alzheimer’s disease. Hoboken: Wiley interdisciplinary reviews RNA; 2018.
Schueller F, Roy S, Vucur M, et al. The role of miRNAs in the pathophysiology of liver diseases and toxicity. Int J Mol Sci. 2018;19(1):261.
Mannucci C, Casciaro M, Minciullo PL, et al. Involvement of microRNAs in skin disorders: a literature review. Allergy Asthma Proc. 2017;38:9–15.
Garo LP, Murugaiyan G. Contribution of MicroRNAs to autoimmune diseases. Cell Mol Life Sci CMLS. 2016;73:2041–51.
Yin H, Zhao M, Wu X, et al. Hypomethylation and overexpression of CD70 (TNFSF7) in CD4+ T cells of patients with primary Sjogren’s syndrome. J Dermatol Sci. 2010;59:198–203.
Alevizos I, Illei GG. MicroRNAs as biomarkers in rheumatic diseases. Nat Rev Rheumatol. 2010;6:391–8.
Meira M, Sievers C, Hoffmann F, et al. miR-126: a novel route for natalizumab action? Mult Scler J. 2014;20:1363–70.
Petri M, Wallace DJ, Spindler A, et al. Sifalimumab, a human anti-interferon-alpha monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheumatol. 2013;65:1011–21.